CVS Health (CVS) has staged a remarkable turnaround after a rocky start to 2026, erasing all early-year losses with its share price jumping more than 25% so far this year. The rally is fueled by upbeat progress across its Medicare segment, prompting a string of sell-side analysts to bump up their price targets. Investors widely believe the stock still has plenty of room to run and could rank among the top-performing blue-chip names in healthcare for the full year.
Mizuho analyst Ann Hynes reiterated her bullish stance on CVS Health on June 8 and raised her price target by 4.5% from $110 to $115 per share. The stock traded around $97 at the time of the upgrade, implying roughly 18.5% upside. Subsequent share gains have narrowed the implied upside to approximately 13% as the stock kept marching higher.
Sustained share appreciation has reshaped broad market sentiment toward the healthcare conglomerate. Investors previously only anticipated modest earnings beats, but a growing cohort now expects CVS to consistently outperform consensus profit estimates over the long haul. Analysts back this upbeat outlook, arguing the stock’s upside ceiling stretches well beyond the newly lifted $115 target.
From a valuation perspective, CVS currently trades at under 13.8 times forward earnings. At the $115 target price, and based on projected 2026 EPS of $7.43, its forward price-to-earnings multiple would climb to around 15.5. The market now views CVS as a diversified healthcare services provider, drawing direct comparisons to peer UnitedHealth Group, which commands a forward multiple near the low 20s. CVS stands poised for a similar valuation rerating, backed by forecasts of double-digit earnings expansion in 2027.
Should CVS’s multiple expand to the high teens or even match UnitedHealth’s 20-times forward earnings level, its stock price could approach $150, unlocking substantial long-term upside.
Robust cash flow fundamentals offer an extra layer of support for the stock. In the latest quarter ending March 31, CVS generated $4.2 billion in operating cash flow. While down from $4.6 billion in the year-ago period, the figure easily covered quarterly dividend outlays of $847 million, which consumed just over 20% of its operating cash flow for the quarter.
Management projects full-year operating cash flow of at least $9.5 billion, more than enough to cover its planned $3.39 billion in annual dividend payments. The firm has paused its customary annual dividend hikes—first to service debt tied to the Aetna acquisition for nearly four years, and again in the current cycle—but ample cash generation eliminates risks of a dividend cut, making its shareholder payout highly secure.
A confluence of positive drivers underpins analysts’ repeated target upgrades: improving momentum in its Medicare business creates a powerful catalyst for share gains, its depressed valuation leaves meaningful rerating potential, and steady operating cash flow safeguards dividend distributions. Market participants remain convinced that the healthcare blue chip’s upward trajectory is far from over.
